I Am Attending the American Association of Cancer Researchers (AACR) Conference in Washington, D.C.
I am in Washington at the AACR conference so my blog posts might be irregular until next Thursday or Friday. I will try and share any interesting or important things I see or learn while [...]
An Article In The Lancet Reported Positive Data From Phase 1-2 Trial Of MDV3100 for men with Advanced Prostate Cancer (4/15/10)
It was announced today that the phase I/II trial of MDV3100 demonstrated positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex. [...]
A Phase I Clinical Trial of DPX-0907 for Advanced Prostate Cancer
As you already know, I am very interested and a strong believer in the future of immunologic therapy. I have written extensively about Provenge and last week I told you about a phase I clinical [...]
Salvage Therapy with High Dose Bicalutamide (Casodex) In Non-metastatic Castration-Resistant Prostate Cancer – It Controls PSA and Disease Progression
Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate [...]
Listening in on the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Reviewing Evidence on the use of Radiation Therapy for Localized Prostate Cancer
Listening in on the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Reviewing Evidence on the use of Radiation Therapy for Localized Prostate Cancer
Chemotherapy, Combining Drugs to Extend Life
The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any [...]